FDA Approves Sanofi’s Tzield for Stage 3 Type 1 Diabetes
Sanofi (EURONEXT: SAN) secures FDA approval for Tzield (teplizumab) in pediatric stage 3 type 1 diabetes, expanding its endocrinology franchise by 15% in revenue potential and positioning it as the ... Read More